New Protocol: Cemiplimab with Chemotherapy in NSCLC


  • Study

    Double-blind, placebo-controlled, phase 3 study

    Untreated advanced or metastatic NSCLC

    Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154))




  • Efficacy

    mOS : 21.9 vs. 13.0 mos (HR = 0.71, p= 0.014)
    mPFS: 8.2 vs. 5.0 mos (HR = 0.56, p < 0.001)
    ORR: 43.3% vs. 22.7% (OR:2.68)
    CR: 2.7% vs. 0%




  • Safety

    Any grade AEs: 95.8% vs 94.1%
    Grade ≥3 AEs: anemia (9.9% vs. 6.5%); neutropenia (5.9% vs 5.8%)




  • Nat Med. 2022; 28(11): 2374–2380

    Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

    http://doi.org/10.1038/s41591-022-01977-y

    Reviewed by Elvin Chalabiyev, MD on Jan 10, 2023